News Bayer gets swift review for Kerendia in type 1 diabetes FDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.
News Joint MHRA/NICE pathway 'benefits industry over patients' LSE pharma policy expert contends the MHRA/NICE aligned pathway is weighted towards industry, and calls for an assessment of its impact on the NHS.
R&D Biopharma’s future in Ireland: Stability, regulation & talen... As increasing global competition from incentives is felt globally, Ireland needs to become even more agile.
Market Access Innovation beyond invention will bring novel medicines to Eu... Unlocking the potential of novel medicines for Europe’s patients demands innovation beyond invention.
R&D On the ICH E20 draft guideline (2025) for adaptive clinical ... A review of the scope, key principles, methodological expectations, and regulatory implications of ICH E20.
News Eisai, Biogen face delay to subcutaneous Leqembi Eisai and Biogen are facing a delay in the FDA review of injectable Leqembi for initial dosing in Alzheimer's, viewed as a key growth driver.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.